Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: a systematic review
With upcoming new treatment modalities for HER2-amplified breast cancer, the stratification of patients who will benefit from such agents is increasingly important. The promising antibody-drug conjugate trastuzumab-deruxtecan, which received accelerated FDA-approval in metastatic breast cancer based on the DESTINY-Breast01 trial, is an example of a novel effective HER2-targeted agent [1]. According to current ASCO-CAP guidelines HER2 is assessed by immunohistochemistry (IHC), complemented by (fluorescence) in situ hybridization (ISH) in case of equivocal (2+) results. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 28, 2022 Category: Cancer & Oncology Authors: Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens Source Type: research
The current clinical landscape of personalized cancer vaccines
The earliest known form of immunotherapy was performed by the American surgeon William Coley in 1890 who treated cancer patients with streptococcal bacterial cultures (dubbed “Coley’s toxin”) and observed tumor regression in some cases [1]. Since then, tremendous amount of work has demonstrated that the human immune system can indeed prevent, control and eradicate cancer cells [1]. Cancer immunotherapy can be classified into two main categories, i.e. passive or act ive, based on their mode of actions. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 24, 2022 Category: Cancer & Oncology Authors: Hajer Guiren Fritah, Rapha ël Rovelli, Cheryl Lai-Lai Chiang, Lana E. Kandalaft Source Type: research
The management of colorectal liver metastases amenable of surgical resection: how to shape treatment strategies according to clinical, radiological, pathological and molecular features
In spite of recent advances in systemic treatments, metastatic colorectal cancer (mCRC) is a highly-lethal disease, with poor chance of long-term survival [1]. However, cure or prolonged disease-free remission are achievable in selected patients with colorectal liver metastases (CRLM) eligible for metastases resection with radical intent [2 –5] . Recent advances in surgical techniques, the availability of active systemic oncological treatments and the wide spread of the multidisciplinary approach have expanded the percentage of patients deemed eligible for radical metastasectomy [6–9]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 20, 2022 Category: Cancer & Oncology Authors: Marco Maria Germani, Beatrice Borelli, Piero Boraschi, Carlotta Antoniotti, Clara Ugolini, Lucio Urbani, Luca Morelli, Gabriella Fontanini, Gianluca Masi, Chiara Cremolini, Roberto Moretto Source Type: research
Compliance to chemoradiation in squamous cell carcinoma of the anus
In squamous cell cancer of the anus (SCCA) standard treatment for localized disease is chemoradiotherapy (CRT) (using 50-56Gy) using concurrent mitomycin C (MMC) and 5-fluorouracil (5FU) or capecitabine - as recommended by ESMO-ESSO-ESTRO, UK intensity-modulated radiation therapy (IMRT) guidelines and National Comprehensive Cancer Network (NCCN) guidelines[1,2,3].Fig 1. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 19, 2022 Category: Cancer & Oncology Authors: Asad Mahmood, Neel Bhuva, Emmanouil Fokas, Robert Glynne-Jones Tags: Controversy Source Type: research
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis
Renal cell carcinoma (RCC) accounts for approximately 400 000 diagnoses and 175 000 deaths each year[1]. Overall, 50%-60% of the patients require systemic treatments for metastatic disease (mRCC)[2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 16, 2022 Category: Cancer & Oncology Authors: Pasquale Lombardi, Marco Filetti, Rosa Falcone, Rossella Di Bidino, Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Giampaolo Tortora, Giovanni Scambia, Gennaro Daniele Tags: Systematic or Meta-analysis Studies Source Type: research
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era
Thyroid cancer is the most common endocrine malignancy, accounting for 3% of all cancers diagnosed annually worldwide [1]. Thyroid cancers can originate from two types of endocrine cells: parafollicular C cells and follicular thyroid cells. Cancers derived from parafollicular C cells are termed medullary thyroid cancers (MTCs) and make up a small proportion of thyroid cancers (2 –3%) [2]. Follicular cell-derived thyroid malignancies account for most thyroid tumours and may be subdivided into: follicular thyroid cancer (FTC; 6–10% of all thyroid cancers); papillary thyroid cancer (PTC; accounting for 65–93% of all thy...
Source: Cancer Treatment Reviews - March 16, 2022 Category: Cancer & Oncology Authors: Jaume Capdevila, Ahmad Awada, Dagmar F ührer-Sakel, Sophie Leboulleux, Patrick Pauwels Source Type: research
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
The treatment paradigm of metastatic renal cell carcinoma (mRCC) has radically changed in the last years. The advent of new vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) such as cabozantinib and lenvatinib, together with the discovery of immuno-oncology (IO) agents as nivolumab, ipilimumab and pembrolizumab, significantly improved survival of mRCC patients [1]. The recent approval of different immune checkpoint inhibitors (ICIs) – based combinations as new first-line options redefined the standard of care, replacing monotherapy with VEGF-targeted therapies for treatment-naïve mRCC...
Source: Cancer Treatment Reviews - March 12, 2022 Category: Cancer & Oncology Authors: Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, Serena Astore, Maria Antonella Cannella, Maria Grazia Maratta, Mimma Rizzo, Elena Verzoni, Camillo Porta, Giampaolo Tortora Tags: Tumour Review Source Type: research
Emergence of Ocular Toxicities Associated with Novel Anticancer Therapeutics: What the Oncologist Needs to Know
Implications for Practice (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 11, 2022 Category: Cancer & Oncology Authors: Azka Ali, Ankit A. Shah, Lauren J. Jeang, Kyle S. Fallgatter, Thomas J. George, David L. DeRemer Tags: Complications of Treatment Source Type: research
Multidisciplinary Clinical Guidance on Trastuzumab Deruxtecan (T-DXd) –Related Interstitial Lung Disease—Focus on Proactive Monitoring, Diagnosis, and Management
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload. [1] The linker remains stable in plasma and is selectively cleaved by cathepsins that are upregulated in tumor cells. [1-4] The cytotoxic payload is present at an approximately 8:1 drug-to-antibody ratio; is membrane permeable, which potentially results in a bystander effect when it is released from HER2-expressing cells and enters neighboring cells (regardless of HER2 expression);...
Source: Cancer Treatment Reviews - March 11, 2022 Category: Cancer & Oncology Authors: Sandra M. Swain, Mizuki Nishino, Lisa H. Lancaster, Bob T. Li, Andrew G. Nicholson, Brian J. Bartholmai, Jarushka Naidoo, Eva Schumacher-Wulf, Kohei Shitara, Junji Tsurutani, Pierfranco Conte, Terufumi Kato, Fabrice Andre, Charles A. Powell Tags: Complications of Treatment Source Type: research
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
Sarcomatoid features in metastasized renal cell carcinoma (mRCC) were historically described as a histopathologic pattern consisting of an apparent pleomorphic mixture of malignant elements arising from the connective tissue, smooth muscle tissue or other tissues[1,2]. More recently, it has been characterized by the presence of malignant spindle cells that usually express markers of both epithelial and stromal differentiation[3] (Image 1). Any presence of sarcomatoid component is enough to determine the tumor as having sarcomatoid features[4,5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 10, 2022 Category: Cancer & Oncology Authors: M ário Fontes-Sousa, Emiliano Calvo Tags: Anti-tumour Treatment Source Type: research
Immunotherapy in advanced anal cancer: is the beginning of a new era?
Anal cancer is a rare disease that accounts for less than 3% of all gastrointestinal tumors [1]. The incidence of its most common histologic variant, squamous cell carcinoma of the anus (SCCA) is 0.5- 2 cases/100.000 per year, although it has been steadily increasing in the latest years [1-5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 8, 2022 Category: Cancer & Oncology Authors: Davide Ciardiello, Luigi Pio Guerrera, Brigida Anna Maiorano, Paola Parente, Tiziana Pia Latiano, Massimo Di Maio, Fortunato Ciardiello, Teresa Troiani, Erika Martinelli, Evaristo Maiello Tags: Anti-tumour Treatment Source Type: research
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
In early invasive breast cancer, neoadjuvant treatments may be recommended before surgery and adjuvant treatments recommended after surgery. These treatments can reduce breast cancer recurrence and mortality, but may increase the risk of death from some other diseases. The evidence on benefits and risks of these treatments is not static but accumulates continuously and is scattered throughout the literature. Therefore, an up-to-date summary is needed for clinical training and to inform treatment decisions in the clinic today. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 3, 2022 Category: Cancer & Oncology Authors: Amanda J. Kerr, David Dodwell, Paul McGale, Francesca Holt, Fran Duane, Gurdeep Mannu, Sarah C Darby, Carolyn W Taylor Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 1, 2022 Category: Cancer & Oncology Source Type: research
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
According to the latest GLOBOCAN data, thyroid cancer accounts for 3% of new cancer diagnoses, being the ninth most frequent cancer worldwide. However, it comprises only 0.4% of all cancer deaths, mainly due to its excellent prognosis [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 28, 2022 Category: Cancer & Oncology Authors: Mar ía San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa Source Type: research
Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350]
The authors regret that the captions given with Figs. 1 –3 in the published article are incorrectly ordered. The correct figure captions with figures are given here. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 23, 2022 Category: Cancer & Oncology Authors: Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, Giulio Metro, Patrick Forde, Alfredo Addeo Tags: Corrigendum Source Type: research
